Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Bicycle Therapeutics plcNASDAQ: BCYC
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $4.94M fell 41.0% year over year, behind the -37.5% change in trailing-twelve-month other income / expenses. Sequentially, it fell 14.4% from the prior quarter. Over 3 fiscal years it compounded at +128.9% a year.
Context
- Other income / expenses amounted to 39.8% of revenue in FY2025, down 62.4 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -41.0% toward the trailing-twelve-month pace of -37.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 28.91M USD
- Year-over-year change
- -19.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.91M | -19.9% |
| FY2024 | 2024-12-31 | 36.08M | +235.9% |
| FY2023 | 2023-12-31 | 10.74M | +345.2% |
| FY2022 | 2022-12-31 | 2.41M | +184.2% |
| FY2021 | 2021-12-31 | (2.86M) | — |
Other Income / Expenses vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's LTM Mar 2026 other income / expenses of $24.78M is the 2nd highest of the 10 companies compared; the peer median is $7M.
- Its year-over-year change of -37.5% is the 7th highest of 9, against a peer median of -11.8%.
- Other income / expenses amounts to 39.0% of revenue for BCYC, versus a peer median of 21.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $191.32M | +1815.8% | — | 1933.9% | |
| LTM Mar 2026 | $24.78M | -37.5% | +128.9% | 39.0% | |
| LTM Mar 2026 | $20.28M | -10.8% | — | 35.0% | |
| LTM Mar 2026 | $18.65M | -30.6% | +97.1% | 21.1% | |
| LTM Mar 2026 | $10.44M | -12.7% | +54.3% | — | |
| LTM Mar 2026 | $7M | +6.0% | +37.7% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $745K | -95.5% | -4.3% | — |
| LTM Dec 2025 | -$1.21M | — | — | 1.0% | |
| LTM Mar 2026 | -$1.86M | -1250.0% | — | 2.7% | |
| LTM Mar 2026 | -$17.66M | +27.0% | — | 22.3% | |
| Peer median (excluding BCYC) | $7M | -11.8% | +46.0% | 21.7% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.7M | 14.46M | 26.98M | 35.28M | 72.59M |
| Cost of Revenue | 0 | 0 | 156.5M | 172.97M | 0 |
| Gross Profit | 11.7M | 14.46M | (129.52M) | (137.69M) | 72.59M |
| Gross Margin | 100.0% | 100.0% | -480.1% | -390.3% | 100.0% |
| Research & Development | 44.88M | 81.61M | 156.5M | 172.97M | 240.28M |
| Selling, General & Admin | 32.44M | 49.51M | 59.83M | 71.46M | 80.02M |
| Operating Expenses | 77.32M | 131.12M | 60.43M | 72.18M | 320.3M |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.18M | 6.42M |
| EBITDA | (64.09M) | (107.21M) | (169.4M) | (164.89M) | (212.18M) |
| EBITDA Margin | -547.9% | -741.3% | -628.0% | -467.4% | -292.3% |
| Operating Income | (65.62M) | (116.65M) | (189.95M) | (209.87M) | (247.72M) |
| Operating Margin | -561.0% | -806.6% | -704.1% | -595.0% | -341.3% |
| Interest Income | 120K | 5.76M | 14M | 34.28M | 28.46M |
| Interest Expense | 2.98M | 3.34M | 3.26M | 1.73M | 206K |
| Other Income / Expenses | (2.86M) | 2.41M | 10.74M | 36.08M | 28.91M |
| Income Before Tax | (68.48M) | (114.24M) | (179.21M) | (173.8M) | (218.81M) |
| Pre-Tax Margin | -585.5% | -789.9% | -664.3% | -492.7% | -301.4% |
| Income Tax Expense | (1.66M) | (1.52M) | 1.46M | (4.77M) | 152K |
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Net Margin | -571.2% | -779.3% | -669.7% | -479.2% | -301.7% |
| EPS (Basic) | (2.67) | (3.80) | (5.08) | (2.91) | (3.16) |
| EPS (Diluted) | (2.67) | (3.80) | (5.08) | (2.90) | (3.16) |
| Weighted Avg Shares | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
| Weighted Avg Shares (Diluted) | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.